Last Update 14 Apr 26

AMGN: Diversified Autoimmune And Cardiovascular Pipeline Will Support Future Cash Generation

Analysts have lifted Amgen's average price target, with changes such as the recent $10, $17, $6, $10 and $15 upward revisions reflecting updated views on its pipeline progress, commercial execution, and refreshed financial models.

Analyst Commentary

Recent Street research on Amgen shows a cluster of higher price targets and fresh coverage that centers on its pipeline, commercial performance, and updated financial models.

Bullish analysts have lifted targets in increments ranging from US$4 to US$30, reflecting revised views on how current products and late stage assets are feeding into their forecasts and valuation work.

Alongside these target changes, new coverage initiations with Hold and Equal Weight ratings point to a more balanced stance from some firms, with comments that Amgen shares look fairly valued after a strong prior run, even as guidance is described as strong and key trial readouts are still ahead.

Bullish Takeaways

Several bullish analysts have raised Amgen price targets by US$4, US$5, US$6, US$10, US$15, US$17, US$20 and US$30, citing refreshed models that incorporate updated 10 K filings, Phase 3 pipeline asset value and recent data discussions with management.
One firm lifted its target to US$375 from US$325 and kept an Equal Weight rating, linking the higher valuation to added Phase 3 pipeline contribution and updated financial inputs, which supports the idea that the pipeline is playing a larger role in target setting.
Another bullish analyst raised a target to US$432 from US$381 and kept an Overweight rating after meetings with management that focused on expansion opportunities for Uplizna, respiratory candidate AMG 104 and autoimmune programs like daxdilimab and dazodalibep, framing these as potential growth drivers in their model.
Jefferies initiated coverage with a Hold rating and a US$350 target, highlighting strong recent commercial execution, removal of regulatory overhangs and a supportive macro backdrop as key reasons the shares are viewed as fairly valued at current levels despite prior gains.

What's in the News

Positive Phase 3 topline results for TEPEZZA delivered via a subcutaneous on body injector in moderate to severe active Thyroid Eye Disease, with a 77% proptosis response rate during the 24 week placebo controlled period and efficacy described as comparable to intravenous TEPEZZA, which has treated more than 25,000 patients worldwide (company announcement).
New subgroup analysis from the Phase 3 VESALIUS CV trial reported that adding Repatha to statins or other LDL C lowering treatments reduced the risk of first major adverse cardiovascular events in high risk primary prevention patients with diabetes, with median achieved LDL C of 44 mg/dL at 96 weeks in the Repatha arm versus 105 mg/dL in the placebo arm (company announcement).
The European Commission approved UPLIZNA as an add on treatment to standard therapy for adults with generalized myasthenia gravis who are anti AChR or anti MuSK antibody positive, expanding its use beyond prior approvals in IgG4 related disease and neuromyelitis optica spectrum disorder (EC approval announcement).
Zai Lab and Amgen entered a global clinical trial collaboration to study Zai Lab’s DLL3 targeting antibody drug conjugate zocilurtatug pelitecan in combination with Amgen’s DLL3 targeting BiTE therapy IMDELLTRA in extensive stage small cell lung cancer, with Amgen sponsoring a global Phase 1b study (company collaboration announcement).
Amgen issued earnings guidance for fiscal 2026, with total revenues expected between US$37.0b and US$38.4b and GAAP EPS expected between US$15.45 and US$16.94 (company guidance).

Valuation Changes

Fair Value: Model fair value remains at $432.0, showing no change in the central valuation estimate used.
Discount Rate: The discount rate moves slightly higher from 7.54% to 7.58%, implying a modestly higher required return in the updated model.
Revenue Growth: The revenue growth assumption edges up from 6.48% to 6.52%, reflecting a small adjustment to projected top line expansion in dollar terms.
Net Profit Margin: The net profit margin assumption nudges higher from 29.56% to 29.63%, indicating a very small change in expected profitability on future dollar sales.
Future P/E: The future P/E multiple moves slightly lower from 22.25x to 22.19x, suggesting a marginally more conservative earnings multiple applied to forward dollar earnings.

6 views

Key Takeaways

Expanding product volumes and AI-driven R&D advancements position Amgen to exceed revenue and margin expectations through frequent, high-impact new launches across key therapeutic areas.
Strong resilience to industry pricing pressures, global expansion, and ample M&A capacity enable Amgen to unlock long-term earnings growth and broaden its market reach.
Policy uncertainty, patent expirations, rising R&D costs, acquisition risks, and biosimilar competition threaten long-term revenue growth, profit margins, and earnings stability.

Catalysts

About Amgen

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.What are the underlying business or industry changes driving this perspective?

Analyst consensus believes Amgen's volume-led sales growth will drive strong revenue, but this likely understates the true trajectory, as double-digit volume expansion now spans 15 products and is accelerating in obesity, rare disease, and biosimilars; this breadth positions Amgen to consistently outperform revenue expectations and deliver operating leverage.
Consensus highlights pipeline momentum, but the combination of accelerated AI-enabled R&D, streamlined dose-escalation strategies, and a robust global late-stage pipeline-spanning obesity (MariTide), oncology (BiTE platform), inflammation, and rare diseases-suggests new product launches will not only be more frequent but also deliver higher peak sales and superior long-term margins than currently recognized.
Amgen's unique resilience to pricing pressures and payer obstacles, aided by leadership in biologics and biosimilars, provides a powerful buffer in an industry facing ongoing net price erosion; this should result in higher-than-expected net margins and free cash flow as biologic adoption increases globally and biosimilar regulations further soften.
The company's extensive global footprint, growing access initiatives, and direct-to-consumer strategies position its therapies for accelerated uptake among the rapidly expanding populations affected by aging and lifestyle-related chronic diseases, supporting a step-change in addressable market size and multi-year top-line compounding growth.
With an increasingly unlevered balance sheet post-Horizon acquisition, Amgen now has exceptional capacity to execute bolt-on M&A and scale pipeline investments in underserved segments like cardiometabolic and genomic medicine, creating upside optionality for sustained earnings growth and outperformance relative to forecasted capital allocation returns.

Amgen Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

This narrative explores a more optimistic perspective on Amgen compared to the consensus, based on a Fair Value that aligns with the bullish cohort of analysts.
The bullish analysts are assuming Amgen's revenue will grow by 6.5% annually over the next 3 years.
The bullish analysts assume that profit margins will increase from 21.0% today to 29.6% in 3 years time.
The bullish analysts expect earnings to reach $13.2 billion (and earnings per share of $24.05) by about April 2029, up from $7.7 billion today. However, there is some disagreement amongst the analysts with the more bearish ones expecting earnings as low as $7.6 billion.
In order for the above numbers to justify the price target of the more bullish analyst cohort, the company would need to trade at a PE ratio of 22.2x on those 2029 earnings, down from 24.5x today. This future PE is greater than the current PE for the US Biotechs industry at 17.7x.
The bullish analysts expect the number of shares outstanding to grow by 0.25% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.58%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Intensifying global efforts to regulate and cap drug prices, highlighted by frequent references to ongoing discussions with government officials and the shifting policy landscape, may restrain Amgen's ability to realize price increases, putting long-term pressure on revenue growth and net margins.
Patent expirations and the rise of biosimilars are already impacting legacy brands like Prolia, which declined in revenue due to lower net selling price and early biosimilar launches; this trend threatens to accelerate as more cornerstone products lose exclusivity, leading to heightened competition and shrinking profit margins.
Elevated research and development expenses are repeatedly mentioned as Amgen ramps investment in late-stage pipeline assets to offset legacy declines-however, increased R&D spending may not consistently yield commercialized products, which could negatively affect earnings stability if clinical failures or delays occur.
The company's strategy includes large-scale acquisitions such as Horizon Therapeutics, with management explicitly acknowledging ongoing integration efforts and additional business development transactions-this raises the risk that anticipated synergies may not materialize, potentially resulting in balance sheet strain and diminished return on invested capital over the long term.
Amgen's growing focus on biosimilars exposes it to industry-wide commoditization and regulatory complexity, with executives noting that market and regulatory environments remain volatile-a reduction in barriers may benefit initial volume but could ultimately drive pricing downward and compress operating margins as competition in the biosimilars space intensifies.

Valuation

How have all the factors above been brought together to estimate a fair value?

The assumed bullish price target for Amgen is $432.0, which represents up to two standard deviations above the consensus price target of $352.03. This valuation is based on what can be assumed as the expectations of Amgen's future earnings growth, profit margins and other risk factors from analysts on the bullish end of the spectrum.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $432.0, and the most bearish reporting a price target of just $200.0.
In order for you to agree with the more bullish analyst cohort, you'd need to believe that by 2029, revenues will be $44.4 billion, earnings will come to $13.2 billion, and it would be trading on a PE ratio of 22.2x, assuming you use a discount rate of 7.6%.
Given the current share price of $349.82, the analyst price target of $432.0 is 19.0% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Amgen?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystHighTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystHighTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystHighTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Biosimilars And Targeted Therapies Will Expand Global Chronic Care Markets